228 related articles for article (PubMed ID: 25724854)
1. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin.
Jones RN; Farrell DJ; Flamm RK; Sader HS; Dunne MW; Mendes RE
Diagn Microbiol Infect Dis; 2015 May; 82(1):73-7. PubMed ID: 25724854
[TBL] [Abstract][Full Text] [Related]
2. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011).
Jones RN; Sader HS; Flamm RK
Diagn Microbiol Infect Dis; 2013 Mar; 75(3):304-7. PubMed ID: 23357293
[TBL] [Abstract][Full Text] [Related]
3. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
[TBL] [Abstract][Full Text] [Related]
4. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
Biedenbach DJ; Ross JE; Fritsche TR; Sader HS; Jones RN
J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
6. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
Jones RN; Turnidge JD; Moeck G; Arhin FF; Mendes RE
Antimicrob Agents Chemother; 2015 Apr; 59(4):2405-9. PubMed ID: 25666152
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
8. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
9. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
Jones RN; Sader HS; Fritsche TR; Hogan PA; Sheehan DJ
J Clin Microbiol; 2006 Jul; 44(7):2622-5. PubMed ID: 16825398
[TBL] [Abstract][Full Text] [Related]
10. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
[TBL] [Abstract][Full Text] [Related]
11. Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.
Jones RN; Wilson ML; Weinstein MP; Stilwell MG; Mendes RE
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):402-5. PubMed ID: 23514756
[TBL] [Abstract][Full Text] [Related]
12. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Streit JM; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
15. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
Sader HS; Mendes RE; Pfaller MA; Flamm RK
J Antimicrob Chemother; 2019 May; 74(5):1306-1310. PubMed ID: 30753485
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
Fritsche TR; Sader HS; Stillwell MG; Jones RN
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
[TBL] [Abstract][Full Text] [Related]
19. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
[TBL] [Abstract][Full Text] [Related]
20. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.
Koeth LM; DiFranco-Fisher JM; McCurdy S
J Vis Exp; 2015 Sep; (103):. PubMed ID: 26381422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
